Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...
Yahoo Finance

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

NEW HAVEN, Conn., September 03, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for ...
Investing

KeyBanc maintains $12 target on Recursion Pharmaceuticals post-acquisition

KeyBanc Capital Markets maintained its Overweight rating for Recursion following the FDA approval. In addition, Recursion announced a $30 million deal with Genentech and plans for a $200 million ...
Seeking Alpha

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (RXRX) (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug ...